NCT03034200View on ClinicalTrials.gov

Phase 2 Study of ONC201 in Neuroendocrine Tumors

PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

August 2, 2017

Primary Completion Date

May 19, 2023

Study Completion Date

May 19, 2023

Conditions
Recurrent Neuroendocrine TumorMetastatic Neuroendocrine Tumor
Interventions
DRUG

ONC201

625mg ONC201 will be given on two consecutive days each week

Trial Locations (1)

44195

Cleveland Clinic Pediatric and Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland

All Listed Sponsors
lead

Peter Anderson

OTHER

NCT03034200 - Phase 2 Study of ONC201 in Neuroendocrine Tumors | Biotech Hunter | Biotech Hunter